Joseph Grieco

Dr. Joseph Grieco joined Tris Pharma in September 2022 and as Vice President of Clinical Development. He leads clinical development and pharmacovigilance, informs asset development, and oversees the operational execution of clinical trials. Joe has an extensive background in clinical development programs in multiple therapeutic areas with a focus on severe rare congenital disorders including lysosomal storage disease, genetically based cognitive disorders, seizure and neo-natal conditions as well as severe ophthalmological conditions. Prior to his current role at Tris, Joe held roles of increasing responsibility in both biotech and academia. His early work began as an academic neuroscientist studying Alzheimer’s disease and Parkinson’s Dementia with a focus on rare congenital cognitive disorders, specifically Angelman and Fragile X Syndrome. Most notably during this tenure he identified the first candidate medicine for the treatment of Angelman syndrome which led to the first ever clinical trial in this population with a severe unmet need. Dr. Grieco holds a Ph.D. in Neuroscience and a M.S. in Medical Science from the University of South Florida, Tampa, Florida.